|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LTB4R |
Gene summary for LTB4R |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LTB4R | Gene ID | 1241 |
| Gene name | leukotriene B4 receptor | |
| Gene Alias | BLT1 | |
| Cytomap | 14q12 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q15722 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1241 | LTB4R | P4T-E | Human | Esophagus | ESCC | 9.62e-03 | 4.64e-02 | 0.1323 |
| 1241 | LTB4R | P5T-E | Human | Esophagus | ESCC | 1.92e-05 | 7.44e-02 | 0.1327 |
| 1241 | LTB4R | P8T-E | Human | Esophagus | ESCC | 9.40e-03 | 2.79e-02 | 0.0889 |
| 1241 | LTB4R | P9T-E | Human | Esophagus | ESCC | 1.59e-06 | 1.78e-01 | 0.1131 |
| 1241 | LTB4R | P10T-E | Human | Esophagus | ESCC | 1.07e-18 | 3.54e-01 | 0.116 |
| 1241 | LTB4R | P12T-E | Human | Esophagus | ESCC | 1.32e-06 | 5.26e-02 | 0.1122 |
| 1241 | LTB4R | P15T-E | Human | Esophagus | ESCC | 4.60e-23 | 4.82e-01 | 0.1149 |
| 1241 | LTB4R | P17T-E | Human | Esophagus | ESCC | 1.04e-06 | 1.76e-01 | 0.1278 |
| 1241 | LTB4R | P20T-E | Human | Esophagus | ESCC | 1.62e-07 | 7.15e-02 | 0.1124 |
| 1241 | LTB4R | P21T-E | Human | Esophagus | ESCC | 3.23e-13 | 1.42e-01 | 0.1617 |
| 1241 | LTB4R | P22T-E | Human | Esophagus | ESCC | 1.24e-14 | 2.06e-01 | 0.1236 |
| 1241 | LTB4R | P26T-E | Human | Esophagus | ESCC | 6.05e-04 | 1.10e-01 | 0.1276 |
| 1241 | LTB4R | P27T-E | Human | Esophagus | ESCC | 1.47e-17 | 2.96e-01 | 0.1055 |
| 1241 | LTB4R | P28T-E | Human | Esophagus | ESCC | 1.05e-45 | 7.19e-01 | 0.1149 |
| 1241 | LTB4R | P30T-E | Human | Esophagus | ESCC | 1.09e-16 | 4.97e-01 | 0.137 |
| 1241 | LTB4R | P31T-E | Human | Esophagus | ESCC | 2.58e-17 | 3.05e-01 | 0.1251 |
| 1241 | LTB4R | P32T-E | Human | Esophagus | ESCC | 1.72e-02 | 9.20e-02 | 0.1666 |
| 1241 | LTB4R | P36T-E | Human | Esophagus | ESCC | 7.84e-03 | 5.59e-02 | 0.1187 |
| 1241 | LTB4R | P37T-E | Human | Esophagus | ESCC | 2.89e-14 | 3.92e-01 | 0.1371 |
| 1241 | LTB4R | P42T-E | Human | Esophagus | ESCC | 1.16e-05 | 2.20e-01 | 0.1175 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000166720 | Esophagus | ESCC | ameboidal-type cell migration | 250/8552 | 475/18723 | 1.22e-03 | 5.97e-03 | 250 |
| GO:001063120 | Esophagus | ESCC | epithelial cell migration | 187/8552 | 357/18723 | 6.05e-03 | 2.23e-02 | 187 |
| GO:009013220 | Esophagus | ESCC | epithelium migration | 188/8552 | 360/18723 | 6.96e-03 | 2.54e-02 | 188 |
| GO:009013020 | Esophagus | ESCC | tissue migration | 190/8552 | 365/18723 | 7.91e-03 | 2.82e-02 | 190 |
| GO:000166719 | Oral cavity | OSCC | ameboidal-type cell migration | 228/7305 | 475/18723 | 3.46e-05 | 3.10e-04 | 228 |
| GO:001063118 | Oral cavity | OSCC | epithelial cell migration | 174/7305 | 357/18723 | 1.04e-04 | 7.70e-04 | 174 |
| GO:009013218 | Oral cavity | OSCC | epithelium migration | 175/7305 | 360/18723 | 1.18e-04 | 8.54e-04 | 175 |
| GO:009013018 | Oral cavity | OSCC | tissue migration | 176/7305 | 365/18723 | 1.92e-04 | 1.29e-03 | 176 |
| GO:00030129 | Skin | AK | muscle system process | 64/1910 | 452/18723 | 4.32e-03 | 2.52e-02 | 64 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LTB4R | SNV | Missense_Mutation | novel | c.326N>A | p.Thr109Lys | p.T109K | Q15722 | protein_coding | deleterious(0.02) | possibly_damaging(0.758) | TCGA-EA-A411-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| LTB4R | SNV | Missense_Mutation | novel | c.401N>T | p.Ala134Val | p.A134V | Q15722 | protein_coding | tolerated(1) | benign(0.015) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| LTB4R | SNV | Missense_Mutation | novel | c.602A>T | p.Tyr201Phe | p.Y201F | Q15722 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-VS-A950-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| LTB4R | SNV | Missense_Mutation | c.217T>C | p.Phe73Leu | p.F73L | Q15722 | protein_coding | tolerated(0.24) | benign(0.018) | TCGA-VS-A9UV-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | PD | |
| LTB4R | insertion | In_Frame_Ins | novel | c.325_326insGTG | p.Thr109delinsSerAla | p.T109delinsSA | Q15722 | protein_coding | TCGA-EA-A411-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| LTB4R | SNV | Missense_Mutation | novel | c.97N>G | p.Leu33Val | p.L33V | Q15722 | protein_coding | tolerated(0.06) | benign(0.018) | TCGA-AA-3930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD |
| LTB4R | SNV | Missense_Mutation | novel | c.263N>T | p.Ala88Val | p.A88V | Q15722 | protein_coding | tolerated(0.53) | benign(0.011) | TCGA-AA-3930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD |
| LTB4R | SNV | Missense_Mutation | c.568T>G | p.Phe190Val | p.F190V | Q15722 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| LTB4R | SNV | Missense_Mutation | novel | c.221N>C | p.Phe74Ser | p.F74S | Q15722 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| LTB4R | SNV | Missense_Mutation | novel | c.362G>A | p.Arg121His | p.R121H | Q15722 | protein_coding | tolerated(0.11) | possibly_damaging(0.88) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1241 | LTB4R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | CHEMBL1742420 | AMELUBANT | |
| 1241 | LTB4R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 135651386 | ||
| 1241 | LTB4R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 178100421 | ||
| 1241 | LTB4R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | Biomed 101 | |||
| 1241 | LTB4R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | Amelubant | AMELUBANT | ||
| 1241 | LTB4R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | CP-195543 | CP-195543 | ||
| 1241 | LTB4R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 178102777 | SC-41390 | |
| 1241 | LTB4R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 178102776 | CP-195543 | |
| 1241 | LTB4R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 178100392 | ||
| 1241 | LTB4R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | LTB 019 |
| Page: 1 2 3 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |